The global Single-Photon Emission Computed Tomography (SPECT) Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Type of Radioisotopes (Tc-99m, Ra-223, Ga-67, I-123, Others), By Application (Oncology, Cardiology, Neurology, Others).
The Single-Photon Emission Computed Tomography (SPECT) Market comprises nuclear imaging systems, gamma cameras, radiopharmaceuticals, and image reconstruction software used in molecular imaging, functional brain imaging, cardiac perfusion studies, and oncology diagnostics. SPECT imaging techniques detect gamma radiation emitted by radiotracers injected into patients, providing three-dimensional images of physiological processes, organ function, and disease pathology. Market trends include hybrid SPECT/CT systems, cardiac SPECT imaging protocols, theranostics applications, radioisotope production innovations, and regulatory approvals for novel radiopharmaceuticals in diagnostic imaging and therapeutic monitoring.
The global Single-Photon Emission Computed Tomography (SPECT) Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Single-Photon Emission Computed Tomography (SPECT) Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Single-Photon Emission Computed Tomography (SPECT) Industry include- Bracco Imaging, Cardinal Health Inc, Curium, Digirad Corp, Gamma Medica Inc, GE Healthcare, Global Medical Solutions, Guerbet, Lantheus Medical Imaging Inc, Neusoft Corp, NTP Radioisotopes SOC Ltd, Spectrum Dynamics Medical.
A significant trend in the Single Photon Emission Computed Tomography (SPECT) market is the integration of hybrid imaging technologies, particularly SPECT/CT and SPECT/MRI systems. Hybrid imaging combines the functional information provided by SPECT with the anatomical detail offered by computed tomography (CT) or magnetic resonance imaging (MRI), enabling comprehensive diagnostic evaluation and improved localization of physiological abnormalities. This trend involves the development of advanced software algorithms, hardware components, and integrated imaging platforms to enhance image registration, co-registration, and fusion of SPECT data with anatomical imaging modalities, offering clinicians valuable insights for accurate diagnosis and treatment planning across a wide range of medical specialties.
The primary driver for the SPECT market is the expanding applications of SPECT imaging in oncology and cardiology. SPECT plays a crucial role in the diagnosis, staging, and monitoring of various cancers, including breast cancer, lung cancer, and lymphoma, by providing functional information about tumor metabolism, perfusion, and receptor expression. Additionally, SPECT myocardial perfusion imaging (MPI) is widely utilized for the assessment of coronary artery disease, myocardial viability, and cardiac function, guiding treatment decisions and risk stratification in patients with suspected or known cardiovascular conditions. As the burden of cancer and cardiovascular diseases continues to rise globally, there's a growing demand for SPECT imaging solutions that offer high sensitivity, specificity, and clinical utility for early detection and management of these prevalent diseases.
An opportunity exists in the advancements in radiotracer development and molecular imaging probes for SPECT imaging applications. Innovations in radiopharmaceutical chemistry, radionuclide production, and targeting ligand design enable the development of novel SPECT tracers with enhanced specificity, affinity, and pharmacokinetic properties for imaging specific molecular targets and biological processes. By investing in research and development efforts aimed at discovering new radiotracers for oncological, cardiovascular, neurological, and musculoskeletal imaging applications, radiopharmaceutical companies can expand the clinical utility of SPECT imaging, address unmet medical needs, and contribute to the advancement of precision medicine and personalized healthcare strategies. Additionally, partnerships with academic institutions, contract research organizations (CROs), and regulatory agencies facilitate the translation of novel radiotracers from preclinical research to clinical practice, unlocking new opportunities for market growth and differentiation in the SPECT imaging segment.
Among the types of radioisotopes used in Single Photon Emission Computed Tomography (SPECT), Tc-99m stands out as the fastest-growing segment. Technetium-99m (Tc-99m) is widely favored in nuclear medicine imaging due to its favorable physical properties, such as its short half-life and optimal energy characteristics for gamma camera detection. Tc-99m radiopharmaceuticals are extensively used across various medical specialties, including oncology, cardiology, neurology, and others, for diagnosing and monitoring a wide range of conditions. The versatility, cost-effectiveness, and widespread availability of Tc-99m-labeled radiotracers contribute to its increasing adoption in clinical practice. Moreover, ongoing advancements in radiopharmaceutical development and imaging technology continue to enhance the diagnostic capabilities and clinical utility of Tc-99m-based SPECT imaging, driving its rapid growth in the medical imaging market. As the demand for precise and efficient diagnostic imaging solutions continues to rise, Tc-99m-based SPECT imaging is poised to play a pivotal role in meeting the evolving healthcare needs across diverse medical disciplines.
By Type of Radioisotopes
Tc-99m
Ra-223
Ga-67
I-123
Others
By Application
Oncology
Cardiology
Neurology
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Bracco Imaging
Cardinal Health Inc
Curium
Digirad Corp
Gamma Medica Inc
GE Healthcare
Global Medical Solutions
Guerbet
Lantheus Medical Imaging Inc
Neusoft Corp
NTP Radioisotopes SOC Ltd
Spectrum Dynamics Medical
* List not Exhaustive
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Single-Photon Emission Computed Tomography (SPECT) Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Single-Photon Emission Computed Tomography (SPECT) Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Single-Photon Emission Computed Tomography (SPECT) Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Single-Photon Emission Computed Tomography (SPECT) Market Size Outlook, $ Million, 2021 to 2030
3.2 Single-Photon Emission Computed Tomography (SPECT) Market Outlook by Type, $ Million, 2021 to 2030
3.3 Single-Photon Emission Computed Tomography (SPECT) Market Outlook by Product, $ Million, 2021 to 2030
3.4 Single-Photon Emission Computed Tomography (SPECT) Market Outlook by Application, $ Million, 2021 to 2030
3.5 Single-Photon Emission Computed Tomography (SPECT) Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Single-Photon Emission Computed Tomography (SPECT) Industry
4.2 Key Market Trends in Single-Photon Emission Computed Tomography (SPECT) Industry
4.3 Potential Opportunities in Single-Photon Emission Computed Tomography (SPECT) Industry
4.4 Key Challenges in Single-Photon Emission Computed Tomography (SPECT) Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Single-Photon Emission Computed Tomography (SPECT) Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Single-Photon Emission Computed Tomography (SPECT) Market Outlook by Segments
7.1 Single-Photon Emission Computed Tomography (SPECT) Market Outlook by Segments, $ Million, 2021- 2030
By Type of Radioisotopes
Tc-99m
Ra-223
Ga-67
I-123
Others
By Application
Oncology
Cardiology
Neurology
Others
8 North America Single-Photon Emission Computed Tomography (SPECT) Market Analysis and Outlook To 2030
8.1 Introduction to North America Single-Photon Emission Computed Tomography (SPECT) Markets in 2024
8.2 North America Single-Photon Emission Computed Tomography (SPECT) Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Single-Photon Emission Computed Tomography (SPECT) Market size Outlook by Segments, 2021-2030
By Type of Radioisotopes
Tc-99m
Ra-223
Ga-67
I-123
Others
By Application
Oncology
Cardiology
Neurology
Others
9 Europe Single-Photon Emission Computed Tomography (SPECT) Market Analysis and Outlook To 2030
9.1 Introduction to Europe Single-Photon Emission Computed Tomography (SPECT) Markets in 2024
9.2 Europe Single-Photon Emission Computed Tomography (SPECT) Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Single-Photon Emission Computed Tomography (SPECT) Market Size Outlook by Segments, 2021-2030
By Type of Radioisotopes
Tc-99m
Ra-223
Ga-67
I-123
Others
By Application
Oncology
Cardiology
Neurology
Others
10 Asia Pacific Single-Photon Emission Computed Tomography (SPECT) Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Single-Photon Emission Computed Tomography (SPECT) Markets in 2024
10.2 Asia Pacific Single-Photon Emission Computed Tomography (SPECT) Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Single-Photon Emission Computed Tomography (SPECT) Market size Outlook by Segments, 2021-2030
By Type of Radioisotopes
Tc-99m
Ra-223
Ga-67
I-123
Others
By Application
Oncology
Cardiology
Neurology
Others
11 South America Single-Photon Emission Computed Tomography (SPECT) Market Analysis and Outlook To 2030
11.1 Introduction to South America Single-Photon Emission Computed Tomography (SPECT) Markets in 2024
11.2 South America Single-Photon Emission Computed Tomography (SPECT) Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Single-Photon Emission Computed Tomography (SPECT) Market size Outlook by Segments, 2021-2030
By Type of Radioisotopes
Tc-99m
Ra-223
Ga-67
I-123
Others
By Application
Oncology
Cardiology
Neurology
Others
12 Middle East and Africa Single-Photon Emission Computed Tomography (SPECT) Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Single-Photon Emission Computed Tomography (SPECT) Markets in 2024
12.2 Middle East and Africa Single-Photon Emission Computed Tomography (SPECT) Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Single-Photon Emission Computed Tomography (SPECT) Market size Outlook by Segments, 2021-2030
By Type of Radioisotopes
Tc-99m
Ra-223
Ga-67
I-123
Others
By Application
Oncology
Cardiology
Neurology
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Bracco Imaging
Cardinal Health Inc
Curium
Digirad Corp
Gamma Medica Inc
GE Healthcare
Global Medical Solutions
Guerbet
Lantheus Medical Imaging Inc
Neusoft Corp
NTP Radioisotopes SOC Ltd
Spectrum Dynamics Medical
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Type of Radioisotopes
Tc-99m
Ra-223
Ga-67
I-123
Others
By Application
Oncology
Cardiology
Neurology
Others
The global Single-Photon Emission Computed Tomography (SPECT) Market is one of the lucrative growth markets, poised to register a 6.4% growth (CAGR) between 2024 and 2030.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
Bracco Imaging, Cardinal Health Inc, Curium, Digirad Corp, Gamma Medica Inc, GE Healthcare, Global Medical Solutions, Guerbet, Lantheus Medical Imaging Inc, Neusoft Corp, NTP Radioisotopes SOC Ltd, Spectrum Dynamics Medical
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2030; Currency: USD; Volume